Figure 2
The effects of CCM111 on immune signaling pathways. Four stable cell lines expressing STAT1/1-, STAT1/2-, STAT3- or NF-κB-dependent luciferase reporters were treated with different concentrations of CCM111 (0, 40, 80, 120, 160 and 240 μg/ml) as shown in (a). The STAT1/2, STAT3 and NF-κB reporters were constructed in the HEK293 cell line. The STAT1/1 was constructed in the HeLa cell line. Cells were treated with individual ligands alone or in combination with different doses of CCM111 as shown in (b–e). The luciferase activity of the NF-κB was detected at 4 hours, and the luciferase activities of STAT1/1, STAT1/2 and STAT3 were measured at 17 hours. The S.D. was performed by Student’s t-test compared to the individual ligand group. *p-value < 0.05, **p-value < 0.01 and ***p-value < 0.001. Results were obtained from three independent replicates.
